← Back to Search

F18 Florbetapir (amyvid) cardiac PET/CT imaging for Cardiac Amyloidosis

Phase 4
Waitlist Available
Led By Chris Mueller, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial will test if a chemotherapy regimen can reduce the amount of amyloid protein in the heart of patients with AL amyloidosis.

Eligible Conditions
  • Cardiac Amyloidosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Relative change in cardiac uptake of 18F florbetapir prior to chemotherapy and after six months of chemotherapy.
Secondary outcome measures
Cardiac response
Hematologic response
Patient related outcomes
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with AL cardiac amyloidExperimental Treatment1 Intervention
Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
614 Previous Clinical Trials
1,162,876 Total Patients Enrolled
Chris Mueller, MDPrincipal InvestigatorMedical College of Wisconsin
~1 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top